Lilly's Orforglipron showing superior HbA1c reduction over oral Rybelsus is a significant...

Lilly's Orforglipron showing superior HbA1c reduction over oral Rybelsus is a significant development. For India, this means a potentially more effective oral GLP-1 option, crucial for diabetes management.

Adherence to injectables remains a major hurdle here. A potent oral drug improves patient compliance and broadens access, potentially shifting market dynamics for pharma companies.

https://pharma.economictimes.indiatimes.com/news/research-and-development/lillys-orforglipron-outclass-rival-rybelsus-in-head-to-head-trial/128834453